Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTRÉE-Lung: Novel Regimens vs SoC in NSCLC
NCT03739710Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2019
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
A Phase 2 trial of feladilimab, belrestotug, GSK6097608B in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Jan 2019; status: completed.
02
Drugs
feladilimabbelrestotugGSK6097608B
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03739710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739710.